Last reviewed · How we verify
Reference-Brinzolamide 1% Ophthalmic suspension
Reference-Brinzolamide 1% Ophthalmic suspension works by reducing intraocular pressure by increasing the outflow of aqueous humor.
Reference-Brinzolamide 1% Ophthalmic suspension works by reducing intraocular pressure by increasing the outflow of aqueous humor. Used for Treatment of ocular hypertension or glaucoma.
At a glance
| Generic name | Reference-Brinzolamide 1% Ophthalmic suspension |
|---|---|
| Sponsor | Actavis Inc. |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase II |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It does this by inhibiting the carbonic anhydrase enzyme in the ciliary epithelium of the eye, which leads to a decrease in the production of aqueous humor. This reduction in intraocular pressure helps to alleviate symptoms of glaucoma and ocular hypertension.
Approved indications
- Treatment of ocular hypertension or glaucoma
Common side effects
- Blepharitis
- Eye irritation
- Headache
Key clinical trials
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE1, PHASE2)
- To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: